Cheng Lin Wang

US Patent:

7501435, Mar 10, 2009

Filed:

Apr 24, 2007

Appl. No.:

11/789288

Inventors:

Kenneth L. Arrington - Philadelphia PA, US
Edward J. Brnardic - Lansdale PA, US
Vadim Y. Dudkin - Lansdale PA, US
Mark E. Fraley - North Wales PA, US
Shaei Y. Huang - Lansdale PA, US
Cheng Wang - King of Prussia PA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/4738
C07D 471/06

US Classification:

514287, 546 64, 544125, 5142332

Abstract:

The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

US Patent:

20090233896, Sep 17, 2009

Filed:

Jun 5, 2006

Appl. No.:

11/921598

Inventors:

Kenneth L. Arrington - Philadelphia PA, US
Vadim Y. Dudkin - Lansdale PA, US
Mark E. Fraley - North Wales PA, US
Jacob M. Hoffman - Lansdale PA, US
Constantine Kreatsoulas - Elkins Park PA, US
Cheng Wang - King of Prussia PA, US

International Classification:

A61K 31/397
C07D 413/14
A61K 31/5377
C07D 401/14
A61K 31/506
C07D 403/00
A61K 31/496
A61P 35/00

US Classification:

5142102, 544121, 5142358, 544124, 5142355, 544333, 514256, 544295, 51425218

Abstract:

The instant invention provides for compounds which comprise substituted pyridyl aminothiazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

US Patent:

20120122899, May 17, 2012

Filed:

Nov 10, 2011

Appl. No.:

13/293166

Inventors:

Ian M. Bell - Harleysville PA, US
Mark E. Fraley - North Wales PA, US
Steven N. Gallicchio - Horsham PA, US
Anthony Ginnetti - Perkasie PA, US
Helen J. Mitchell - Richboro PA, US
Daniel V. Paone - Lansdale PA, US
Donnette D. Staas - Holland PA, US
Heather E. Stevenson - Philadelphia PA, US
Cheng Wang - Fort Washington PA, US
C. Blair Zartman - Hatfield PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/439
A61K 31/527
A61P 25/06
C07D 471/20

US Classification:

5142651, 546 15, 514278, 544230

Abstract:

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

US Patent:

20120122900, May 17, 2012

Filed:

Nov 10, 2011

Appl. No.:

13/293177

Inventors:

Ian M. Bell - Harleysville PA, US
Mark E. Fraley - North Wales PA, US
Steven N. Gallicchio - Horsham PA, US
Anthony Ginnetti - Perkasie PA, US
Helen J. Mitchell - Richboro PA, US
Daniel V. Paone - Lansdale PA, US
Donnette D. Staas - Holland PA, US
Cheng Wang - Fort Washington PA, US
C. Blair Zartman - Hatfield PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/437
A61K 31/527
A61P 25/06
C07D 471/20

US Classification:

5142651, 546 15, 514278, 544230

Abstract:

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

US Patent:

20120135977, May 31, 2012

Filed:

Sep 28, 2011

Appl. No.:

13/247009

Inventors:

Douglas C. Beshore - Lower Gwynedd PA, US
Vadim Dudkin - Lansdale PA, US
Robert M. Garbaccio - Lansdale PA, US
Adam W. Johnson - Harleysville PA, US
Scott D. Kuduk - Harleysville PA, US
Jason W. Skudlarek - Audubon PA, US
Cheng Wang - Fort Washington PA, US
Mark E. Fraley - North Wales PA, US

International Classification:

A61K 31/4192
C07D 401/12
A61K 31/4439
C07D 403/12
A61K 31/506
A61K 31/497
C07D 471/04
A61K 31/437
A61K 31/496
C07D 413/12
A61K 31/5377
A61K 31/454
A61K 31/551
A61K 31/55
C07D 417/12
A61K 31/541
A61P 25/00
A61P 25/18
C07D 249/18

US Classification:

51421018, 514359, 548259, 5462684, 514338, 544333, 544316, 514256, 514274, 544405, 51425505, 546121, 514300, 544366, 51425406, 544132, 5142342, 546199, 514321, 540575, 514218, 51421021, 540524, 51421208, 544 582, 5142285

Abstract:

The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

US Patent:

20120149677, Jun 14, 2012

Filed:

Aug 16, 2010

Appl. No.:

13/391315

Inventors:

Vadim Y. Dudkin - West Point PA, US
Mark E. Fraley - West Point PA, US
Cheng Wang - West Point PA, US
Robert M. Garbaccio - West Point PA, US
Douglas C. Beshore - West Point PA, US
Scott K. Kuduk - West Point PA, US
Jason W. Skudlarek - West Point PA, US

International Classification:

A61K 31/4439
C07D 403/12
C07D 495/04
C07D 403/14
C07D 401/14
C07D 417/14
A61K 31/497
A61K 31/4709
A61K 31/506
A61K 31/519
A61K 31/444
A61K 31/541
A61K 31/438
A61P 25/00
A61P 25/18
C07D 401/12

US Classification:

51421016, 5462684, 544405, 546157, 544310, 544316, 544278, 544319, 546256, 544238, 544 582, 540575, 540492, 514338, 51425505, 514312, 514274, 5142601, 514269, 514333, 5142285, 51421021, 51421018

Abstract:

The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

US Patent:

20130231358, Sep 5, 2013

Filed:

Nov 10, 2011

Appl. No.:

13/884632

Inventors:

Ian M. Bell - Harleysville PA, US
Mark E. Fraley - North Wales PA, US
Steven N. Gallicchio - Horsham PA, US
Anthony Ginnetti - Perkasie PA, US
Helen J. Mitchell - Richboro PA, US
Daniel V. Paone - West Point PA, US
Donnette D. Staas - Holland PA, US
Cheng Wang - Fort Washington PA, US
Blair C. Zartman - Hatfield PA, US
Heather E. Stevenson - Ardmore PA, US

International Classification:

C07D 471/04
C07D 487/04

US Classification:

5142651, 546 15, 514278, 544230

Abstract:

The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

US Patent:

20140005214, Jan 2, 2014

Filed:

Mar 14, 2012

Appl. No.:

14/005595

Inventors:

Ian M. Bell - Harleysville PA, US
Mark E. Fraley - North Wales PA, US
Steven N. Gallicchio - Horsham PA, US
Helen J. Mitchell - Richboro PA, US
Cheng Wang - Fort Washington PA, US

International Classification:

C07D 401/12

US Classification:

514278, 546 15

Abstract:

The present invention is directed to piperidinone carboxamide spirohydantoin derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.